Competition will heat up in anti-obesity medicine market

Competition is about to heat up in the domestic anti-obesity medicines market, as the US-based Abbott Reductil's patent is scheduled for expiration on this July 1 and a number of its generics are lining up side by side.

Sales of Reductil (sibutramine) reached over 25 billion won since its release in 2001, making it one of the top-selling drugs in the country.

The market for such drugs is ...